GlassScriptPhysician profile
Peter Juergensen
NPI 1982699799
$9,112.10
in general payments reported to CMS, 2019-2025
22 companies · $864 in 2025
The $864 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,091 · 2022: $819 · 2023: $812 · 2024: $525 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,175 · Education: $27.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.66 |
| Education | $27.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $5,936.23 | 2021-2023 | Veltassa, Korsuva |
| Amgen INC. | $1,044.53 | 2021-2025 | Parsabiv, Aranesp, Tavneos |
| Travere Therapeutics, INC. | $300.15 | 2021-2025 | Filspari |
| Akebia Therapeutics INC | $263.02 | 2021-2025 | Vafseo, Auryxia |
| Fresenius USA Marketing, INC. | $198.05 | 2022-2025 | Velphoro, Velphoro, Crit-Line |
| Novo Nordisk INC | $177.29 | 2024-2025 | Ozempic, Rybelsus, Rivfloza |
| Ardelyx, INC. | $171.77 | 2023-2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $155.05 | 2021-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $148.44 | 2021-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $137.84 | 2022-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $99.62 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $87.01 | 2022-2025 | Acthar |
| Genzyme Corporation | $72.71 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $71.30 | 2021 | |
| Glaxosmithkline, LLC. | $54.70 | 2021-2025 | Benlysta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $37.95 | 2021 | |
| Calliditas Therapeutics US INC. | $36.15 | 2024 | |
| Apellis Pharmaceuticals, INC. | $33.04 | 2025 | Empaveli |
| Lilly USA, LLC | $24.02 | 2023 | Jardiance |
| Kyowa Kirin, INC. | $23.08 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.06 | 2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $19.09 | 2025 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Juergensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.